Federal hemp rules could wipe out Sisters of the Valley’s CBD line

Sisters of the Valley says new federal hemp rules set for Dec. 11 could make every CBD product it sells noncompliant, forcing a shift toward licensed cannabis partnerships. The California collective warns the change could hit longtime customers, cut into already-sinking sales and put its farm at risk.

Why it matters: - The new federal hemp standard could force Sisters of the Valley out of its current CBD business. - The change could remove access for customers who have relied on the Sisters’ topical salve and other full-spectrum hemp medicines for years. - The loss of the CBD line could also threaten the California farm that has supported the organization’s work since its earliest years.

What happened: - Sisters of the Valley says the federal hemp restrictions set to take effect Dec. 11 would make its existing CBD products noncompliant. - The new definition caps finished hemp-derived cannabinoid products at 0.4 milligrams of combined total THC and certain similar cannabinoids per container. - The California collective says its full-spectrum formulations would not meet that standard. - Sister Kate, the founder, published a new essay arguing the rules could erase the company’s current CBD line while pushing the organization toward a different business model.

The details: - Sisters of the Valley has built its medicines around full-spectrum plant extracts for nearly 12 years. - The organization tested CBD isolate in 2015 while working with a university in Italy. - The Sisters say isolate did not perform well in their salve and was also rejected for ingestible formulations. - Their topical salve took more than a decade to develop and uses natural ingredients chosen for absorption plus full-spectrum hemp extract. - Removing cannabinoids could leave a compliant product, but not the product customers have been using. - Sister Kate wrote, “Then we would have salve. Just salve.” - Sister Camilla said customers care about whether the medicine works, not the regulatory label. - Monthly sales have fallen from about $100,000 before the pandemic to less than 10% of that level now. - California regulatory changes have blocked renewal of state certifications the company previously held. - Payment and banking restrictions have narrowed the platforms available to hemp businesses. - Square told the Sisters their CBD-focused online store must close by Nov. 10. - Sister Kate wrote that private platforms and financial institutions can move before Congress does. - The Dec. 11 date is also the current federal government funding deadline.

Between the lines: - The federal rule change is colliding with a company that was already under pressure from falling sales and tighter business infrastructure. - The Sisters appear to be treating licensing as a survival strategy, not a brand pivot. - The shift would move the organization away from manufacturing and shipping every product itself and toward licensing intellectual property to regulated partners. - That approach could preserve the mission while reducing dependence on platforms, banking access and direct fulfillment. - The company’s experience in Canada shows the Sisters have previously tried to help customers adapt when regulations cut off access. - Sister Camilla said losing the farm is a real possibility, not a rhetorical one.

What’s next: - Sisters of the Valley is expanding licensing work in California and Oregon. - The organization is using those markets to learn what partnerships require, including inventory reporting, distribution, budtender education and marketing support. - The Sisters are also exploring international licensing opportunities. - Sister Esme said the dispensary market is showing that the Sisters do not have to manufacture and ship every product themselves to keep the mission going. - The essay closes with the view that the mission remains the same even if the route changes.

The bottom line: - The Dec. 11 hemp rule could force Sisters of the Valley to abandon its current CBD line, but the organization is already building a licensing model to keep its plant-medicine mission alive.